Challenging the problem of 'fit': advancing the regenerative medicine industries in the United States, Britain and Japan

This article follows the evolution of biopharmaceutical firms as they bore great uncertainty and risks in their endeavours to commercialise new therapies – through the regenerative medicine industry in the United States, Britain and Japan. Despite its beginnings in the 1970s, regenerative medicines have yet to become a widely accepted form of medicine. A large part of the problem lay with the lack of ‘fit’ with the broader health context. This article illustrates how the trajectory of the sector was shaped, not only by the nature of the technology, but also by the complex contexts in which firms were embedded